TET2 and myelodysplastic syndrome: Moreover, a recent large cross-sectional analysis of (n = 750, 249) patients with MDS across the United States revealed that patients with TET2, DNMT3A, and AXSL1 mutations were associated with a high prevalence of PAD (prevalence among individuals aged <65 and >65 years was 14.5% and 43.2%, respectively; p > 0.0001) and CAD (prevalence among individuals aged <65 and >65 years was 9.1% and 17.3%, respectively; p < 0.04) [29].